{"id":"W4398194425","doi":"10.1016/j.annonc.2024.03.005","title":"Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Sirtex Medical; Ipsen; Boston Scientific Corporation; Incyte; Eisai; AstraZeneca; Ono Pharmaceutical; Bristol-Myers Squibb","keywords":"Ipilimumab; Nivolumab; Medicine; Tolerability; Sorafenib; Internal medicine; Adverse effect; Hepatocellular carcinoma; Regimen; Oncology; Surgery; Gastroenterology; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001171873,0.0005351017,0.0009564739,0.0003082208,0.000286172,0.0006829147,0.0003561584,0.0004288802,0.0009979631],"category_scores_gemma":[0.0006656887,0.0002320353,0.001139296,0.0003073675,0.0003123629,0.0003450071,0.0002309826,0.0009238044,0.0002288311],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008161476,"about_ca_system_score_gemma":0.0006424209,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001407676,"about_ca_topic_score_gemma":0.003395943,"domain_scores_codex":[0.9996657,0.0001462383,0.00002792423,0.00004984815,0.00004428262,0.00006596896],"domain_scores_gemma":[0.9994862,0.00008498794,0.0001162645,0.00003627384,0.0000288316,0.0002473542],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.568807,0.02653368,0.1404057,0.001127986,0.008301858,0.0009904712,0.0003883947,0.004871071,0.03295301,0.0001971943,0.005976662,0.2094469],"study_design_scores_gemma":[0.1852367,0.3560295,0.4352497,0.0001275912,0.0053852,0.001277394,0.0001736591,0.003777002,0.005275854,0.0001935861,0.007177148,0.0000966917],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9959061,0.002716331,0.0001417609,0.000119414,0.00004084618,0.0001311578,0.0003602096,0.00002029513,0.0005638947],"genre_scores_gemma":[0.9968849,0.001092985,0.000220453,0.000222947,0.00007135756,0.0001005144,0.0008886886,0.00000386369,0.0005143872],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001407676,"threshold_uncertainty_score":0.006197512,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06001887754482442,"score_gpt":0.2881822019860163,"score_spread":0.2281633244411919,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}